INDUSTRY SYMPOSIUM TIMETABLE

Friday, December 5, 2014

 
Hall A
Infertility
Hall B
Fetomaternal
Hall C 
Reproduction
Hall E
Fetomaternal
08:30-10:00
- Supported by IBSA Educational Program
 
- Supported by Perkin Elmer
   
10:20-11:50 INNOVATION AND QUALITY: FROM STIMULATION TO PREGNANCY (Con't)      
12:10-13:40  
- Supported by Roche
   
14:30-16:00   PRENATAL DIAGNOSIS IN THE ERA OF NIPT - Supported by Illumina
14:30-15:30
Supportetd by Actavis
 
 
16:30-18:00
   
- Supported by Roche

 

Saturday, December 6, 2014

 
Hall A
Infertility
Hall C
Reproduction
12:10-13:40 12:10-12:40
Genea embryo review incubator
- Supported lecture by Genea Biomedx
Supported by Gedeon Richter
 
14:30-15:00 Clinical Applications of oocyte
and embryo Vitrification
- Supported lecture by Kitazato
 
 

 

 

INFERTILITY SESSIONS (Hall A)

FRIDAY, DECEMBER 5, 2014 

08:30-10:00
INNOVATION AND QUALITY: FROM STIMULATION TO PREGNANCY (Hall A)
IBSA Educational program
Capsule
The IBSA Educational workshop will host distinguished experts presenting innovations in clinical and laboratory aspects 
Chairpersons
Bart C.J.M Fauser, Netherlands
Rene Frydman,
France
 
Endocrinology
Understanding steroids in clinical practice  
Philippe Bouchard, France
 
Thyroid Function and ART 
Brigitte VelkeniersBelgium
 
Biology
Developmental origins of ovarian reserve
Nick S. Macklon, UK

 

10:20-11:50
INNOVATION AND QUALITY: FROM STIMULATION TO PREGNANCY - CON'T (Hall A)
IBSA Educational program
Chairpersons
Rene Frydman, France
Philippe Bouchard, France
 

Biology - Con't

Oocyte developmental competence: in search of a transcriptional signature
Maurizio Zuccotti, Italy

 
High Tech
Debate: CGH array improves IVF outcome
Yes: Simon Fishel, UK
No: Rita Vassena, Spain
Discussion

 

FETOMATERNAL SESSIONS (Hall B)

08:30-10:00
PRE-ECLAMPSIA: EARLY PREDICTION AND PREVENTION (Hall B)
Supported by Perkin Elmer
Chairperson
Dietmar Schlembach, Germany
 
Pre-eclampsia prediction: Combined screening at 11-13 weeks
Jacques Jani, Belgium
 
Prevention of pre-eclampsia and IUGR with aspirin
Emmanuel Bujold, Canada
 
Screen and prevention of Preeclampsia - The health economic perspective
Dietmar Schlembach, Germany

   

12:10-13:40
ANGIOGENIC FACTORS IN PREECLAMPSIA: DIAGNOSIS, PREDICTION AND IMPACT ON CLINICAL MANAGEMENT (Hall B)
Supported by Roche

 

Capsule

Increasingly, data are demonstrating the importance of angiogenic factors in the clinical management of preeclampsia. In this session new data from 2 important clinical studies will be presented. The PROGNOSIS study demonstrates the use of sFlt-1/PlGF ratio in prediction of short-term outcome in pregnant women with suspected preeclampsia. The PreOS study is an open study assessing the impact of the angiogenic factors in the routine clinical management of patients
Chairperson Harald Zeisler, Austria
Shaun Brennecke, Australia
 
Preeclampsia and angiogenic factors: An overview
Elisa Llurba Olivé, Spain
  PROGNOSIS Study results: The prediction of short term outcome in pregnant women with suspected preeclampsia
Stefan Verlohren, Germany

  PreOS study results: Influence of sFIt-1 and PIGF on decision-making of physicians in pregnant women with suspicion of preeclampsia
Holger Stepan, Germany

   

14:30-16:00
PRENATAL DIAGNOSIS IN THE ERA OF NIPT (Hall B)
Supported by Illumina
Capsule
Since its initial introduction into the prenatal screening/testing spectrum of care, the field of non-invasive prenatal testing (NIPT) has evolved and expanded rapidly.  Although originally developed for autosomal aneuploidy detection of chromosomes 21, 18 and 13 in the high-risk pregnancy population, NIPT using genome-wide massively parallel sequencing of cell free DNA in maternal plasma also has the potential to expand testing beyond these common aneuploidies and beyond the high risk pregnancy population.  Since its inception, testing for certain sex chromosome aneuploidies and certain microdeletions already has become possible.  As this testing continues to evolve and expand, it prompts the question of what does the future hold for NIPT. This session will address the following questions about expanding the technology: Can this testing be expanded to the general obstetrical population? Can this testing be expanded beyond chromosomes 21, 18, 13, X and Y?. In addition, the challenges faced by clinicians are also an important aspect of this rapidly evolving field; therefore, this session also will address considerations for incorporating NIPT into the general obstetric practice, as well as the nuances around NIPT results. 
Chairpersons
Nan Okun, Canada
Mark Evans, USA
  NIPT in the general obstetrical population: Results, lessons and insights from the CARE study
Sucheta Bhatt, USA
  Clinical considerations for incorporating NIPT into your practice
Eran Borenstein, USA
  Biological considerations of discordant results and test failures
Steven Warsof, USA 
 
Potential expansion of NIPT: Microdeletion panels to the whole genome panels and beyond
Yuval Yaron, Israel

   

REPRODUCTION SESSION (Hall C)

14:30-15:30
DIAFERT FOLLICULAR FLUID G-CSF TEST: FROM THEORY TO LAB PRACTICE (Hall C)
Supportetd by Actavis
Chairpersons
Bart C.J.M. Fauser, Netherlands
Jacques Cohen, USA
 
Relevance of embryo competence for successful IVF, and role of GCSF
Bart C.J.M. Fauser , Netherlands
 
Diafert test in the daily laboratory practice
Fabian Somers
 
Discussion

 

REPRODUCTION SESSION (Hall E)

16:30-18:00
MEET THE EXPERT SESSION - ANGIOGENIC FACTORS: HOW CAN THEY INFLUENCE PATIENT MANGEMENT? (Hall E)
Supported by Roche
Capsule

Angiogenic factors are increasingly important in the management of patients with suspected preeclampsia. In this session investigators from the PreOS study will present clinical cases illustrating the impact of sFIt-1/PIGF ratio on patient management.

Moderator

Holger Stepan, Germany

Presenters
Dietmar Schlembach, Germany
Angela Ramoni, Austria

 

SATURDAY, DECEMBER 6, 2014 

INFERTILITY SESSION (Hall A)

12:10-13:40
TIME-LAPSE TECHNOLOGY: WHO OFFERS WHAT? 
Supported by Genea Biomedx
12:10-12:40

Genea embryo review incubator
Tammie Roy

 

 14:30 - 16:00
OOCYTE FREEZING
Supported by KITAZATO-Dibmed
Chairpersons
Jacques Cohen, USA
Michael Grynberg, France
 
Clinical applications of oocyte and embryo virtification
Dominic Stoop, Belgium
 
Vitrified oocytes and embryo banking
Ana Cobo, Spain
 
Effects on gene expression in vitrification and slow freezing
Samir Hamamah, France

  

REPRODUCTION SESSION (Hall C)

12:10-13:40
FIBROIDS IN OB/GYN AND INFERTILITY (Hall C)
Supported by Gedeon Richter/Preglem
Capsule
Effective surgical management of endoscopic symptomatic fibroids requires extreme surgical skills. Specific Progesterone Receptor Modulators (SPRMs) are emerging as effective treatment in reducing fibroid size and delaying surgical treatment, but do they have a place in managing symptomatic fibroids before infertility treatments?
Chairpersons
Bart C.J.M. Fauser, Netherlands
Attila Vereczkey, Hungary
Jacques Donnez, Belgium
 
SPRMs mechanism of action on fibroids
Philippe Bouchard, France
 
Surgical or medical treatment for fibroids?
Jacques Donnez, Belgium
 
Limitation of laparoscopic myomectomy
Rudi Campo, Belgium
 
Hysteroscopic myomectomy in infertility: Limitations and complications
Jacques Hamou, France